Work Here?
United Therapeutics Corporation
Work Here?
Biotech company develops PAH therapies
United Therapeutics Corporation
Work Here?
Biotech company develops PAH therapies
Overview
United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.
About United Therapeutics Corporation
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
N/A
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1996
Simplify's Take
What believers are saying
- Q1 2026 cash and investments reached $3.8 billion, with no debt.
- March 2026 ADVANCE OUTCOMES met its primary endpoint with high statistical significance.
- Tyvaso DPI revenue rose 9% in Q1 2026, offsetting nebulized Tyvaso erosion.
What critics are saying
- Nebulized Tyvaso sales fell 22% in Q1 2026, exposing franchise cannibalization.
- Ralinepag remains unapproved, and DPI requires nonclinical, phase 1, and pivotal studies.
- Varda’s microgravity program faces orbital processing, reentry, and scale-up failures before commercialization.
What makes United Therapeutics Corporation unique
- United Therapeutics combines approved rare-lung drugs with organ-manufacturing moonshots.
- May 13, 2026 Varda partnership explores microgravity formulations for pulmonary medicines.
- Ralinepag DPI extends MannKind’s Tyvaso DPI delivery model into PAH and fibrosis.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.5B
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Holidays
Paid Vacation
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Conference Attendance Budget
Professional Development Budget
Professional Certification Support
Tuition Reimbursement
Stock Options
Company Equity
Employee Stock Purchase Plan
Relocation Assistance
Employee Referral Bonus
Performance Bonus
Profit Sharing
Sabbatical Leave
Hybrid Work Options
Remote Work Options
Flexible Work Hours
ParentAL Leave
Stock Price
Company News
Here is a summary of the article: Investment analysis platform StockStory has identified two mid-cap stocks worth buying and one to avoid. The Trade Desk, a cloud-based advertising platform, trades at $23.53 per share with a market capitalisation of $11.21 billion. The company posted 22% annual revenue growth over the past two years and boasts a 20.3% operating margin. United Therapeutics, which develops treatments for chronic lung diseases, has a market capitalisation of $23.24 billion. The company achieved 16.9% annual revenue growth over two years whilst demonstrating strong free cash flow generation and improving returns on capital. StockStory advises avoiding Builders FirstSource, a construction materials manufacturer. The company experienced 5.7% annual sales declines over the past two years, with eroding returns on capital and declining earnings per share.
United Therapeutics has published full Phase 3 TETON-2 trial data for nebulised Tyvaso in idiopathic pulmonary fibrosis in the New England Journal of Medicine. The study demonstrated preservation of lung function and reduced clinical worsening in IPF patients. If approved by the FDA, Tyvaso would become the first and only inhaled anti-fibrotic treatment for IPF, significantly expanding United Therapeutics' addressable market. The company's shares currently trade at $536.12, with one-year returns of 74.5%. The publication in a top-tier journal represents a significant milestone for the drug developer. Investors are now monitoring potential FDA review milestones and how IPF could influence revenue beyond the current $3.2 billion base, though regulatory or reimbursement challenges remain key risks.
United Therapeutics shares fell 7.2% after the biotechnology company reported fourth-quarter revenue of $790.2 million, missing analysts' consensus estimates of over $805 million. Whilst revenue grew 7% year-over-year, Tyvaso sales, though up 12%, also fell short of projections. The company did beat earnings expectations with adjusted earnings of $7.70 per share versus the forecasted $7.10. However, the revenue miss overshadowed the earnings beat, prompting negative market reaction. The stock has shown relatively low volatility over the past year, with only eight moves greater than 5%. United Therapeutics is currently trading at $500.08 per share, near its 52-week high of $535.10. Shares are flat year-to-date.
United Therapeutics reported fourth-quarter 2025 results, with full-year revenue surpassing $3 billion for the first time, representing 11% growth. Fourth-quarter revenue reached $790 million, whilst Tyvaso generated $464 million with dry-powder inhaler sales growing 24% year-over-year. The company plans to file its soft-mist treprostinil inhaler, Tresmi, for approval this year, targeting a 2026 commercial launch. Early studies suggest the device could reduce coughing by up to 90% compared to dry-powder alternatives. Near-term catalysts include a once-daily "super prostacyclin" readout next week and TETON-1 IPF trial results next month, with potential launch by June 2027. The company's Zeno xenotransplant programme has transplanted two patients, targeting a commercial product by 2030.
United Therapeutics missed Wall Street's revenue expectations in Q4 2025, reporting $790.2 million against estimates of $810.4 million, though sales rose 7.4% year on year. The biotechnology company's GAAP profit of $7.70 per share beat analyst estimates by 14%. The company, which develops treatments for chronic lung diseases and pulmonary hypertension, has demonstrated solid long-term performance with 16.5% annualised revenue growth over five years. However, its operating margin declined to 45.1% from 48.6% in the prior-year quarter. Analysts expect revenue to remain flat over the next 12 months, representing a deceleration from recent growth rates. United Therapeutics has a market capitalisation of $20.38 billion.
United Therapeutics Corporation is Hiring for 63 Jobs on Simplify!
Find jobs on Simplify and start your career today
About United Therapeutics Corporation
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
N/A
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1996
United Therapeutics Corporation is Hiring for 63 Jobs on Simplify!
Find jobs on Simplify and start your career today